Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4

US6900179B2 · kind B2 · utility

Inventors

• Eugene D. Thorsett · Moss Beach, US
• Christopher Semko · Fremont, US
• Dimitrios Sarantakis · Newtown, US
• Michael A. Pleiss · Sunnyvale, US
• Anthony Kreft · Langhorne, US
• Andrei W. Konradi · Burlingame, US
• Francine S. Grant · Redwood City, US
• Darren B. Dressen · San Francisco, US
• Susan Ashwell · Plainsboro, US
• Reinhardt Baudy · Doylestown, US
• Louis J. Lombardo · Montgomery, US

Key dates

• Filing date: Nov 15, 2001
• Grant date: May 31, 2005
• Expiry date: Dec 20, 2022

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.